Press Release: Immunovia appoints new Senior Director Investor Relations and Corporate Communications
Press Release: Immunovia appoints new Senior Director Investor Relations and Corporate Communications
Immunovia appoints new Senior Director Investor Relations and Corporate Communications
Immunovia 任命新的投資者關係和企業傳播高級總監
PR Newswire
PR Newswire
LUND, Sweden, Nov. 26, 2021
瑞典隆德，2021年11月26日
LUND, Sweden, Nov. 26, 2021 /PRNewswire/ -- Immunovia AB (publ) announces that Tobias Bülow has been appointed new Senior Director Investor Relations and Corporate Communications, taking up his position January 15. Tobias has s solid IR and Corporate Communications background with extensive experience from international high-tech companies.
瑞典隆德，2021年11月26日 /PRNewswire/ — Immunovia AB（publ）宣佈，托比亞斯·布洛被任命爲新的投資者關係和企業傳播高級總監，將於1月15日上任。Tobias擁有紮實的投資者關係和企業傳播背景，擁有來自國際高科技公司的豐富經驗。
Tobias joins Immunovia from Mycronic AB (publ), where he most recently held the position of Director Investor Relations. Previous experiences include Director Financial Communications at the radiation therapy company Elekta AB (publ).
托比亞斯從Mycronic AB（publ）加入Immunovia，他最近擔任該公司的投資者關係總監。之前的經歷包括放射治療公司Elekta AB（publ）的財務傳播總監。
"I am very pleased to welcome Tobias to Immunovia and the role as Senior Director Investor Relations and Corporate Communications. Tobias has a solid international background from leading positions and companies. I am convinced he has the drive, skills, and experience to contribute in shaping Immunovia's continued journey," says Patrik Dahlen, CEO of Immunovia.
“我很高興歡迎托比亞斯加入Immunovia並擔任投資者關係和企業傳播高級總監。Tobias在領先地位和公司方面擁有紮實的國際背景。我堅信他有動力、技能和經驗，可以爲塑造Immunovia的持續旅程做出貢獻。” Immunovia首席執行官帕特里克·達倫說。
For more information, please contact:
欲瞭解更多信息，請聯繫：
Patrik Dahlen, CEO Immunovia
Immunovia 首席執行官帕特里克·達倫
Email: patrik.dahlen@immunovia.com
電子郵件：patrik.dahlen@immunovia.com
Tel: +46 73 376 76 64
電話：+46 73 376 76 64
About Immunovia
關於 Immunov
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer based on Immunovia's proprietary test platform called IMMray(TM). Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".
Immunovia AB是一家診斷公司，正在基於Immunovia的專有測試平臺Immray（TM）開發和商業化用於早期發現癌症的高精度血液檢測。測試基於抗體生物標誌物微陣列分析，使用先進的機器學習和生物信息學來挑選出一組表明某種疾病的相關生物標誌物。因此，形成了獨特的 “疾病生物標誌物特徵”。
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
該公司成立於2007年，以瑞典隆德大學免疫技術系和CREATE健康癌症中心的癌症研究和開創性研究爲基礎。
The first product, IMMray(TM) PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1.
第一款產品immRay（TM）pancan-d正在一些世界上最大的胰腺癌高危人羣臨床研究中進行臨床評估，這些研究是針對胰腺癌高危人羣，Panfam-1、Pansym-1和Pandia-1。
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray(TM) PanCan-d test, the first blood-based test dedicated to the early detection of pancreatic cancer on the market, is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
2017 年，Immunovia, Inc. 在美國馬薩諸塞州馬爾伯勒成立。immRay (TM) pancan-D 測試是市場上第一款專門用於胰腺癌早期檢測的血液檢測，由實驗室開發的測試 (LDT) 僅通過 Immunovia, Inc. 提供。欲瞭解更多信息，請參閱：www.immouviainc.com。
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
Immunovia的股票（IMMNOV）在斯德哥爾摩納斯達克上欲瞭解更多信息，請訪問 www.immunovia.com。
This information was brought to you by Cision http://news.cision.com
這些信息是由 Cision 帶給你的 http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications, c3461283
https://news.cision.com/immunovia-ab/r/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications，c3461283
The following files are available for download:
以下文件可供下載：
https://mb.cision.com/Main/13121/3461283/1502042.pdf Press release (PDF)
https://mb.cision.com/Main/13121/3461283/1502042.pdf 新聞稿 (PDF)
View original content:https://www.prnewswire.com/news-releases/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications-301432301.html
查看原創內容：https://www.prnewswire.com/news-releases/immunovia-appoints-new-senior-director-investor-relations-and-corporate-communications-301432301.html
SOURCE Immunovia AB
來源 Immunovia
譯文內容由第三人軟體翻譯。